Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer.
アブストラクト The risk of dementia after androgen deprivation therapy (ADT) in patients with advanced prostate cancer (PCa) remains controversial. This study aimed to evaluate the association between ADT and the incidence of dementia in patients with PCa. We identified patients newly diagnosed with PCa in the National Health Insurance Database of Taiwan from 1 January 2002 to 30 June 2016 and in The Health Improvement Network of the United Kingdom (UK) from 1 January 1998 to 31 March 2018. We classified patients with PCa into ADT and ADT-naive groups. Propensity score (PS) methods were used to minimize the differences in characteristics between the groups. We performed a Cox proportional hazard model to obtain the adjusted hazard ratio (HR) to compare the incidence of dementia between the groups. Our ADT group comprised 8743 and 73,816 patients in Taiwan and the UK, respectively, which were matched 1:1 to ADT-naive patients by PS. The incidence rates of dementia in the ADT group were 2.74 versus 3.03 per 1000 person-years in the ADT naive groups in Taiwan, and 2.81 versus 2.79 per 1000 person-years in the UK. There was no statistical difference between ADT and ADT-naive groups (adjusted HR: 1.12; 95% confidence interval (CI): 0.87-1.43 in Taiwan and adjusted HR: 1.02; 95% CI: 0.85-1.23 in the UK). We found no association between the incidence of dementia and ADT in patients with advanced PCa in either database. Further studies are warranted to evaluate other possible triggers of incident dementia in patients receiving ADT for advanced PCa. 投稿日 2021/8/8 投稿者 Liu, Jui-Ming; Shen, Chin-Yao; Lau, Wallis C Y; Shao, Shih-Chieh; Man, Kenneth K C; Hsu, Ren-Jun; Wu, Chun-Te; Lai, Edward Chia-Cheng ジャーナル名 Cancers 組織名 Division of Urology, Department of Surgery, Taoyuan General Hospital, Ministry of;Health and Welfare, Taoyuan 33004, Taiwan.;School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences,;College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.;Research Department of Practice and Policy, UCL School of Pharmacy, London WC1N;1AX, UK.;Centre for Safe Medication Practice and Research, Department of Pharmacology and;Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong;Kong.;Department of Pharmacy, Keelung Chang Gung Memorial Hospital, Keelung 20401,;Taiwan.;Cancer Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical;Foundation, Hualien 97002, Taiwan.;College of Medicine, Tzu Chi University, Hualien 97004, Taiwan.;Department of Urology, Keelung Chang Gung Memorial Hospital, Keelung 20401, Pubmed リンク https://www.ncbi.nlm.nih.gov/pubmed/34359762/